4 Healthcare Stock Stories Starting Off the Short Week

AbbVie (NYSE:ABBV): Closing price $37.55

AbbVie and its partner Roche have suspended five studies on its experimental leukemia and lymphoma drug, following the deaths of two patients from tumor lysis syndrome, according to spokeswoman Tracy Sorrentino for AbbVie. The complication arose from the rapid destruction of malignant cells after treatment that can trigger acute kidney failure. The event occurs most often with large tumors like those found in leukemia and lymphoma patients, according to the National Institutes of Health. AbbVie was the drug firm that split off from Abbott Laboratories at the beginning of the year.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

abbv